SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ReShape Lifesciences Inc. (RSLS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 33/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RSLS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-481,394.00 |
$786.66K |
$-23.36M |
-2969.6% |
| 2017 |
$-176,009.00 |
$1.29M |
$-33.82M |
-2627.3% |
| 2018 |
$-370,876.00 |
$606.71K |
$-81.15M |
-13375.7% |
| 2019 |
$-137,167.00 |
$15.09M |
$-74.21M |
-491.8% |
| 2020 |
$-48,193.90 |
$11.3M |
$-21.63M |
-191.4% |
| 2021 |
$-16,438.40 |
$13.6M |
$-61.93M |
-455.4% |
| 2022 |
$-6,316.20 |
$11.24M |
$-46.21M |
-411.2% |
| 2023 |
$-110.88 |
$8.68M |
$-11.39M |
-131.2% |
| 2024 |
$-13.83 |
$8.01M |
$-7.13M |
-89.1% |
| 2025 |
$0.00 |
$319.71K |
$-10.48M |
-3277.2% |
